Famar
- Company typePrivate
- Founded1949
- HeadquartersAthens, Greece
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Famar firmographics
Firmographics- Name
- Famar
- Legal name
- FAMAR Health Care Services
- Website
- https://famar-group.com
- Company type
- Private
- Founded year
- 1949
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Famar industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
Keywords
Where Famar is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices8 records
Markets served
Famar business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Contract Development Services: R&D and development services for pharmaceutical products including formulation development, analytical services, regulatory support, and tech transfer
- Contract Manufacturing Services: Commercial manufacturing of pharmaceutical products across various dosage forms for global pharmaceutical companies
- Product Dossier Sales: Sale of proprietary pharmaceutical dossiers (e.g., BIMATOPROST) with long-term manufacturing agreements
- Distribution and Logistics Services: Pharmaceutical distribution services in Greece including warehousing, labeling, order fulfillment, and transportation
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom pharmaceutical manufacturing and development services |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Famar product offering
Product offeringCore offering
FAMAR is a European pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers development, manufacturing, quality, regulatory and distribution services across a network of 7 production sites, 2 R&D centers and 1 distribution center. The company manufactures more than 1,800 products in 80 international markets, covering solid dose forms, liquids and semi-solids, sterile injectables, lyophilized products, HPAPIs, and consumer care/cosmetics for pharmaceutical companies and biotechs.
Product overview
FAMAR is a leading European pharmaceutical contract development and manufacturing organization (CDMO) providing end-to-end services from development through production to distribution. The company operates as a single integrated platform organized around six core service areas: Pharmaceutical and Consumer Care Development Services, Manufacturing (covering solid dose, liquid/semi-solid, sterile, and consumer care/cosmetic products across seven production sites), Quality Services, Regulatory Affairs, and Logistics/Distribution. The portfolio includes specialized offerings such as HPAPI Products Manufacturing and COMPASS by FAMAR (ready-to-use solutions). The company supplies more than 1,800 products across 80 international markets through its network of 7 production sites, 2 R&D centers, and 1 distribution center.
Differentiator
Problem solved
Functional benefit
Brands
- COMPASS by FAMAR: A business segment providing agile and ready-to-use solutions and services as a leading CDMO
Products and services
- Pharmaceutical Development Services Comprehensive pharmaceutical development including pre-formulation, formulation, investigational medicinal products (IMP), industrialization, and analytical development for sterile liquids, solids and semi-solids. Targeted at pharmaceutical companies requiring R&D and tech transfer support.
- Consumer Care Development Development services for cosmetics, medical devices and biocides including formulation, regulatory compliance, safety assessment, stability studies and technical file preparation. Targeted at consumer care and personal care companies.
- Manufacturing Services Contract manufacturing across solid dose forms (tablets, capsules, effervescent), liquids and semi-solids (syrups, creams, gels), sterile dosage forms (injectables, ampoules, vials, lyophilized), and consumer care/cosmetic products across seven European production sites.
- Quality Services Comprehensive quality services including regulatory intelligence, supplier compliance auditing, analytical method transfer, stability studies, product quality risk management, process validation and annual product quality reviews for pharmaceutical clients.
- Regulatory Affairs Services Scientific and technical regulatory affairs including CTD module preparation, regulatory gap analysis, compliance assessments, regulatory submission strategy and health authority communication support for pharma clients.
- Logistics and Distribution Services End-to-end pharmaceutical distribution including receiving, storage, labeling, repackaging, order processing, transportation (ambient and cold-chain), returns/recalls and inventory control. Processes approximately 735,000 orders and 210 million packs annually across Greece.
- HPAPI Products Manufacturing High Potency Active Pharmaceutical Ingredient handling with dedicated non-GMP areas for toxicological studies and GMP conditions for Safebridge 3A HPAPIs including investigational medicinal products Phase I/II manufacturing.
- COMPASS by FAMAR Agile and ready-to-use CDMO solutions and services segment launched in October 2023, providing faster engagement options for pharmaceutical customers via a dedicated website at compassbyfamar.com.
Quantifiable outcome
- Top 5% of companies assessed by EcoVadis worldwide - Gold medal
- +2 more outcomes
Companies that use Famar
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles5 records
Famar technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Famar partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- GE HealthCareflagshipContract manufacturing agreement for iodine-based contrast media production at Homburg site in Germany. Commercial supply expected to start in 2028 with capacity target of 25 million patient doses annually by 2031, expanding GE HealthCare's manufacturing capacity in Europe.
- D-SightcoreStrategic partnership for CMC development and clinical batch manufacturing of eye drops solution for diabetic retinopathy treatment. FAMAR provides state-of-the-art GMP manufacturing facilities and CMC expertise while D-Sight contributes innovative therapeutic approach.
- LavipharmcoreCollaboration where FAMAR serves as contract manufacturer for Lavipharm's analgesic products Lonarid N and Lonalgal. Partnership enhances domestic Greek pharmaceutical market competitiveness and ensures consistent efficient production.
- Medicom HealthcarecoreAsset Purchase Agreement for BIMATOPROST dossier sale with 5-year minimum Manufacturing and Supply Agreement. FAMAR develops and manufactures preservative-free eye drop solution for global commercialization by Medicom.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Famar competitors and assessment
Company assessmentDirect peers
- Hovione: European CDMO with particular strength in HPAPI handling, particle engineering, and integrated API-to-drug-product services. Highly comparable to FAMAR's HPAPI and lyophilization capabilities, and competes in the same integrated CDMO segment targeting complex small molecules and potent compounds.
- Recipharm: European-headquartered CDMO offering similar contract development and manufacturing services across solid dose, sterile, and semi-solid dosage forms. Highly comparable in scale, customer base, and service portfolio, and one of the most direct competitive comparables for FAMAR's mid-tier European CDMO positioning.
- Corden Pharma: European CDMO platform offering contract development and manufacturing across APIs, drug products, and packaging for small molecules and biologics. Comparable integrated service model with similar customer base among global pharmaceutical companies seeking mid-tier European supply.
- Aenova: European pharmaceutical CDMO with broad service portfolio covering solid, semi-solid, liquid, and sterile dosage forms across multiple manufacturing sites in Europe. Directly comparable in scale, customer profile (global pharma), and integrated development-to-commercial manufacturing model.
- Fareva: Privately held European CDMO with manufacturing sites across Europe and globally, providing contract manufacturing and packaging for pharmaceuticals, cosmetics, and consumer care. Closely comparable to FAMAR's mix of pharma and consumer care manufacturing across multiple dosage forms and dosage-format specialization.
- Sterling Pharma Solutions: European CDMO focused on API development and manufacturing with growing drug product capabilities. Comparable as a mid-tier European CDMO serving global pharma customers, with overlap in HPAPI handling and small-molecule contract manufacturing.
- Delpharm: European CDMO specializing in sterile and non-sterile pharmaceutical contract manufacturing with multi-site operations across France, Europe, and Canada. Particularly comparable given that Delpharm acquired 5 of FAMAR's former sites (€250M turnover, 1,300 employees) from prior ownership in 2019, directly illustrating service and capability overlap.
Emerging players
- Eurofins CDMO: European CDMO services business spun out of Eurofins, offering contract development and manufacturing for small molecules and biologics. Comparable as a growing European CDMO competing for mid-sized pharma programs, though smaller and more focused than FAMAR's broader dosage form portfolio.
Broad incumbents
- Catalent: One of the largest global CDMOs with extensive capabilities across oral, sterile, and biologic dosage forms including softgel, biologics, and cell/gene therapy. Operates as a broader incumbent than FAMAR in terms of scale, technology breadth, and geographic footprint, but competes for the same pharma outsourcing budgets.
- Piramal Pharma Solutions: Global CDMO with strong HPAPI and sterile injectable capabilities across North America, Europe, and Asia. Overlaps with FAMAR in HPAPI handling, sterile fill-finish, and contract development services, but operates at meaningfully larger scale and global geographic reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights8 records
Customer concentration
Famar social profiles
Digital presenceFamar compliance and trust
Trust signalCompliance22 records
Famar financial estimates
Financial estimateRevenue estimate
Valuation estimate
Famar leadership team
Management profileNumber of profiles
Profiles10 records
Famar funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Famar M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Famar
What does Famar do?
FAMAR is a European pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers development, manufacturing, quality, regulatory and distribution services across a network of 7 production sites, 2 R&D centers and 1 distribution center. The company manufactures more than 1,800 products in 80 international markets, covering solid dose forms, liquids and semi-solids, sterile injectables, lyophilized products, HPAPIs, and consumer care/cosmetics for pharmaceutical companies and biotechs.
Is Famar a public or private company?
Famar is a private company. It is classified as private equity controlled and is currently operating.
When was Famar founded?
Famar was founded in 1949. It employs 1,001 to 5,000 people.
Where is Famar based?
Famar is headquartered in Athens, Greece, in the Europe region.
How does Famar make money?
Four revenue lines are on record. Contract Development Services are the primary driver. The others are contract Manufacturing Services, product Dossier Sales and distribution and Logistics Services.
Who are Famar's main competitors?
Direct peers on record are Hovione, Recipharm, Corden Pharma, Aenova, Fareva, Sterling Pharma Solutions and Delpharm. Eurofins CDMO is listed as an emerging player. Broad incumbents are Catalent and Piramal Pharma Solutions.
Does Famar have an API?
No public API is recorded for Famar.
What industry is Famar in?
Famar's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 5122.